PRFX Key Statistics, Chart & Performance
The current stock price of PRFX is 0.6869 USD. In the past month the price increased by 7.03%. In the past year, price decreased by -77.98%.
PRFX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PRFX. When comparing the yearly performance of all stocks, PRFX is a bad performer in the overall market: 96.51% of all stocks are doing better.
PRFX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRFX. PRFX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PRFX Financial Highlights
Over the last trailing twelve months PRFX reported a non-GAAP Earnings per Share(EPS) of -32.16. The EPS increased by 81.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -130.69% | ||
| ROE | -172.78% | ||
| Debt/Equity | 0 |
PRFX Forecast & Estimates
PRFX Ownership
PRFX Latest News, Press Relases and Analysis
About PRFX
Company Profile
PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The firm is focused on reformulating established pain therapeutics using an extended-release drug-delivery system designed to prolong postoperative analgesia and reduce reliance on opioids. The firm's product, PRF-110, is an oil-based, long-acting formulation of ropivacaine applied directly into surgical wounds to provide localized, extended pain relief, and the Company has also developed patented versions combining ropivacaine with dexamethasone to enhance both analgesic and anti-inflammatory effects. The firm's development strategy leverages available legal means to accelerate commercialization of improved non-opioid pain-management products.
Company Info
PRF TECHNOLOGIES LTD
65 Yigal Alon St.
TEL AVIV-YAFO 6745442 IL
CEO: Ilan Hadar
Employees: 2
Phone: 97237177051
PRF TECHNOLOGIES LTD / PRFX FAQ
What does PRF TECHNOLOGIES LTD do?
PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The firm is focused on reformulating established pain therapeutics using an extended-release drug-delivery system designed to prolong postoperative analgesia and reduce reliance on opioids. The firm's product, PRF-110, is an oil-based, long-acting formulation of ropivacaine applied directly into surgical wounds to provide localized, extended pain relief, and the Company has also developed patented versions combining ropivacaine with dexamethasone to enhance both analgesic and anti-inflammatory effects. The firm's development strategy leverages available legal means to accelerate commercialization of improved non-opioid pain-management products.
What is the stock price of PRF TECHNOLOGIES LTD today?
The current stock price of PRFX is 0.6869 USD. The price decreased by -2.98% in the last trading session.
What is the dividend status of PRF TECHNOLOGIES LTD?
PRFX does not pay a dividend.
What is the ChartMill rating of PRF TECHNOLOGIES LTD stock?
PRFX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in PRF TECHNOLOGIES LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRFX.
Can you provide the short interest for PRFX stock?
The outstanding short interest for PRF TECHNOLOGIES LTD (PRFX) is 1.81% of its float.